baloxavir marboxil
Xofluza
Pharmaceutical company: Genentech
NEW INDICATION & DOSAGE
Treatment of acute, uncomplicated influenza in patients who have been symptomatic for no more than 48 hours, who are otherwise healthy
Children age 5 and older weighing 80 kg or more: 80 mg PO as a single dose.
Children age 5 and older weighing 20 to less than 80 kg: 40 mg PO as a single dose.
Postexposure influenza prophylaxis
Children age 5 and older weighing 80 kg or more: 80 mg PO as a single dose.
Children age 5 and older weighing 20 to less than 80 kg: 40 mg PO as a single dose.
Children age 5 and older weighing less than 20 kg: 2 mg/kg PO as a single dose.
Released: October 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
belimumab
Benlysta
Pharmaceutical company: GlaxoSmithKline
NEW INDICATION & DOSAGE
Active lupus nephritis in patients who are receiving standard therapy
Children age 5 and older: 10 mg/kg IV infusion every 2 weeks for first three doses, then every 4 weeks thereafter.
Released: October 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
ibrutinib
Imbruvica
Pharmaceutical company: Pharmacyclics and Janssen Biotech
NEW INDICATION & DOSAGE
Chronic graft-versus-host disease (GVHD) after failure of one or more lines of systemic therapy
Children age 12 and older: 420 mg PO once daily until GVHD progresses, underlying malignancy recurs, unacceptable toxicity occurs, or patient no longer requires treatment.
Children age 1 to less than 12 years: 240 mg/m2 PO once daily (maximum dose 420 mg) until GVHD progresses, underlying malignancy recurs, unacceptable toxicity occurs, or patient no longer requires treatment.
Released: October 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
relugolix–estradiol–norethindrone acetate
Myfembree
Pharmaceutical company: Myovant Sciences
NEW INDICATION & DOSAGE
Management of moderate to severe pain associated with endometriosis
Adults: 1 tablet PO daily for up to 24 months.
Adjust-a-dose: If use with oral P-glycoprotein inhibitors can’t be avoided, give relugolix–estradiol–norethindrone acetate first, and separate dosing by at least 6 hours.
Released: October 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer
ustekinumab
Stelara
Pharmaceutical company: Janssen Biotech
NEW INDICATION & DOSAGE
Acute psoriatic arthritis
Children ages 6 to 17 weighing more than 100 kg with coexistent moderate-to-severe plaque psoriasis: Initially, 90 mg subcut; repeat dose in 4 weeks, followed by maintenance dose of 90 mg subcut every 12 weeks.
Children ages 6 to 17 weighing 60 kg or more: Initially, 45 mg subcut; repeat dose in 4 weeks, followed by maintenance dose of 45 mg subcut every 12 weeks.
Children ages 6 to 17 weighing less than 60 kg: Initially, 0.75 mg/kg subcut; repeat dose in 4 weeks, followed by maintenance dose of 0.75 mg/kg subcut every 12 weeks.
Released: October 2022
Nursing Drug Handbook
© 2022 Wolters Kluwer